Tiziana Life Sciences has developed an investigational technology for the treatment of Covid-19.
The approach involves the use of a handheld inhaler or nebuliser to directly deliver anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This is expected to support the company’s development of a fully-human anti-IL6R mAb, TZLS-501, to treat Covid-19.
Tiziana Lifesciences chairman Gabriele Cerrone said: “Direct delivery of anti-IL-6R mAb to the lungs using a portable handheld inhaler or nebuliser is a rapid and immediate therapy for children and adults infected with Covid-19.
“Importantly, this treatment with our fully human anti-IL-6R mAb (TZLS-501) has the potential to be a long-term therapy to halt progression and reduce mortality in patients with Covid-19, as a portion of the population may not opt to utilise a vaccine.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
